Erika joins our growing group of industry seasoned advisors who's guidance enables our team to create bespoke solutions to acquiring top talent that is often out of the reach of traditional search firms.
We are incredibly fortunate to welcome Erika De Boever to join our Scientific Advisory Board. Erika brings over 20 years of Clinical Development, Program and Translational Medicine experience gained in top pharmaceutical, academic and biotechnology institutions. Erika is an authority on Rare Disease and Gene Therapy Approaches.
Over the course of her illustrious career Erika has worked on small and large molecules at all stages of clinical development, and has led translational medicine projects. She played a key role in the development and approval of Strimvelis, the first pediatric gene therapy for the treatment of ADA-SCID, while at GSK and held the role of Deputy Director at the prestigious Orphan Disease Center at the University of Pennsylvania.
Erika earned her PhD and MPH at University of Michigan.
Again, we could not be more delighted to include Erika to our growing group. It's thrilling to know that true industry experts such as Erkia, Sean, Kirsten and Rod are willing to embrace Intelisci's mission. By harnessing true industry knowledge we gain a deeper understanding of staffing challenges through each stage of drug development and as a result, we can provide increased efficiency and accuracy throughout the recruitment process.
Σχόλια